Male Breast Carcinoma — Trials

Male Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

104 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: H. Lee Moffitt Cancer Center and Research Institute
Termination share: 34%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 51–73 of 73 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00070252	Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer	completed	Phase 1 / Phase 2	53	National Cancer Institute (NCI)NIH	1	May 4, 2015	clinicaltrials
NCT01131234	Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	completed	Phase 1	20	National Cancer Institute (NCI)NIH	1	Dec 23, 2014